1-16051724-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000085.5(CLCNKB):c.1312C>T(p.Arg438Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000229 in 1,613,726 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R438H) has been classified as Pathogenic.
Frequency
Consequence
NM_000085.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152048Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 250988Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135694
GnomAD4 exome AF: 0.0000219 AC: 32AN: 1461678Hom.: 0 Cov.: 33 AF XY: 0.0000193 AC XY: 14AN XY: 727162
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152048Hom.: 0 Cov.: 33 AF XY: 0.0000539 AC XY: 4AN XY: 74264
ClinVar
Submissions by phenotype
Bartter disease type 3 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 29, 2024 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 1997 | - - |
Pathogenic, criteria provided, single submitter | research | HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology | Jul 30, 2024 | ACMG codes: PS3_Strong, PS4_Strong, PM2_Moderate, PP3_Supporting, PP4_Supporting - |
not provided Pathogenic:2Uncertain:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 27, 2022 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 438 of the CLCNKB protein (p.Arg438Cys). This variant is present in population databases (rs121909133, gnomAD 0.007%). This missense change has been observed in individuals with Bartter syndrome (PMID: 9326936, 21631963, 28381550, 31115572). ClinVar contains an entry for this variant (Variation ID: 7593). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CLCNKB protein function. Experimental studies have shown that this missense change affects CLCNKB function (PMID: 10831588, 11734858). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. This variant disrupts the p.Arg438 amino acid residue in CLCNKB. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10906158, 23703872, 28381550, 31115572, 32857947). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | May 10, 2018 | - - |
Uncertain significance, no assertion criteria provided | literature only | Martin Pollak Laboratory, Beth Israel Deaconess Medical Center | - | - - |
Bartter disease type 3;C4310805:Bartter disease type 4B Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 26, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at